Mindfulness-Oriented Recovery Enhancement (MORE) in Heroin Addiction

Description

In this study, neuroimaging of reward processing, drug cue reactivity and inhibitory control is used before and immediately after 8 weeks of two types of group therapy in individuals with opioid addiction; clinical outcomes will be assessed before, immediately and three months after treatment. Results could point to factors that track and predict recovery with treatment, offering clinicians markers that can be used for enhancing precision medicine with the goal of reducing morbidity and mortality associated with opiate addiction.

Conditions

Opiate Use Disorder

Talk to us

Study Overview

On this page

Study Details

Study overview

In this study, neuroimaging of reward processing, drug cue reactivity and inhibitory control is used before and immediately after 8 weeks of two types of group therapy in individuals with opioid addiction; clinical outcomes will be assessed before, immediately and three months after treatment. Results could point to factors that track and predict recovery with treatment, offering clinicians markers that can be used for enhancing precision medicine with the goal of reducing morbidity and mortality associated with opiate addiction.

Neuroimaging Response Inhibition and Salience Attribution Changes During Mindfulness-based Treatment of Human Heroin Addiction

Mindfulness-Oriented Recovery Enhancement (MORE) in Heroin Addiction

Condition
Opiate Use Disorder
Intervention / Treatment

-

Contacts and Locations

New York

Icahn School of Medicine at Mount Sinai, New York, New York, United States, 10029

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Ability to understand and give informed consent
  • * Males and Females 18-64 years of age
  • * DSM-5 diagnosis of OUD with heroin as the primary drug of choice
  • * Stabilized on methadone or other form of MAT.
  • * DSM-5 diagnosis for schizophrenia or developmental disorder (e.g., autism)
  • * Head trauma with loss of consciousness
  • * History of neurological disease of central origin including seizures
  • * Cardiovascular disease including high blood pressure and/or other medical conditions, including metabolic, endocrinological,oncological or autoimmune diseases, and infectious diseases common in iOUD including Hepatitis B and C or HIV/AIDS
  • * Metal implants or other MR contraindications

Ages Eligible for Study

18 Years to 64 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Icahn School of Medicine at Mount Sinai,

Rita Goldstein, PhD, PRINCIPAL_INVESTIGATOR, Icahn School of Medicine at Mount Sinai

Nelly Alia-Klein, PhD, STUDY_DIRECTOR, Icahn School of Medicine at Mount Sinai

Study Record Dates

2025-06-30